# A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants

> **NCT03232983** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 28 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY900014 (SC)
- **DRUG:** LY900014 (IV)

## Key facts

- **NCT ID:** NCT03232983
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-14
- **Primary completion:** 2017-11-09
- **Final completion:** 2017-11-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232983, "A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03232983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*